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Case ReportSmall-Cell Carcinoma in Association With a
Mature Cystic Teratoma of the Ovary:
A Case Report With Literature Review
Karina E. Hew,1 Kimberley Studeman,2 Panayotis Ledakis,3
Arvind Bakhru,4 Neil B. Rosenshein1Clinical Practice Points
 Malignant transformation of mature cystic teratoma
(MCT) is a rare event, occurring in 1% to 2% of cases.
Small-cell carcinoma arising from an MCT is particu-
larly rare, with only 3 other cases described in the
English literature.
 We report a case of a 54-year-old para 1 female who
was found to have advanced-stage small-cell carci-
noma of the ovary in association with a MCT. The
clinicopathological features, treatment regimen, and
outcome of this patient were compared with the other
cases described in the literature to evaluate the
prognostic signiﬁcance of this unusual subtype of
ovarian cancer.
 Small-cell carcinoma of the ovary arising from a
mature cystic teratoma is a rare form of ovarian
cancer. It is usually of the pulmonary subtype and
is treated with the same chemotherapeutic regimen
as small-cell lung cancer. The prognostic signiﬁ-
cance of this unusual cancer subtype remains
uncertain.Clinical Ovarian and Other Gynecologic Cancer, Vol. 6, No. 1/2, 53-7 ª 2014 Elsevier Inc. All rights reserved.
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Malignant transformation of a mature cystic teratoma (MCT)
is a well-documented event that occurs in 1% to 2% of cases of
MCTs undergo malignant transformation.1-3 The most common
malignancies arising from MCTs are squamous cell carcinomas,
accounting for 80% to 90% of cases.4,5 Malignant transformation
involving small-cell carcinoma of the ovary is particularly rare, with
only 3 cases reported in the English literature.6-8 Primary small-cell
carcinoma of the ovary can be divided into a pulmonary and a
hypercalcemic type.9 The hypercalcemic type is thought to be
present in two-thirds of cases.10 They demonstrate aggressive bio-
logic behavior and high rates of local and distant recurrence. These
neuroendocrine carcinomas are thought to have poor prognoses.11,121Department of Obstetrics and Gynecology, The Gynecologic Oncology Center
2Department of Pathology
3Department of Medical Oncology and Hematology
Mercy Medical Center, Baltimore, MD
4Department of Obstetrics and Gynecology, University of Michigan Comprehensive
Cancer Center, Ann Arbor, MI
Submitted: Mar 18, 2013; Revised: Sep 8, 2013; Accepted: Dec 18, 2013; Epub:
Dec 27, 2013
Address for correspondence: Karina E. Hew, MD, The Gynecologic Oncology Center,
Weinberg Building, 6th Floor, Mercy Medical Center, 301 St Paul Place, Baltimore,
Maryland 21202
E-mail contact: karinahew04@hotmail.com
2212-9553/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2013.12.006It has also been put forward that malignant transformation of an
MCT, particularly to squamous cell carcinoma, carries a worse
prognosis than primary squamous cell carcinoma of the ovary.13,14
However, little is known about the natural history, optimal treat-
ment regimens, or prognosis when an MCT undergoes trans-
formation to a small-cell carcinoma of the ovary.Case Description
The patient is a 54-year-old gravida 1 para 1 married white
female who originally presented in February 2010. She presented
with a 1-month history of abdominal pain and increased abdominal
girth. A computed tomography scan of her abdomen and pelvis
revealed a 15  10  13-cm right pelvic mass and ascites. A par-
acentesis was performed resulting in 4 L of bloody, cloudy perito-
neal ﬂuid with atypical cells and increased nuclear cytoplasmic ratio.
Her cancer antigen 125 serum level was 519 U/mL. Abnormal
physical ﬁndings were conﬁned to the abdomen, which was grossly
distended, with left lower quadrant tenderness, present bowel
sound, and a positive ﬂuid wave result with shifting dullness.
Imaging studies did not reveal any overt distant metastases.
The patient underwent an optimal primary debulking proce-
dure. She had an uneventful intraoperative course and received
2 units of packed red blood cells. An intraoperative frozen-sectionClinical Ovarian and Other Gynecologic Cancer December 2013 - 53
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54 -diagnosis revealed an undifferentiated carcinoma arising from a
mature cystic teratoma.
The ﬁnal pathology report described a small-cell carcinoma
arising in association with an 18-cm mature cystic teratoma of the
right ovary. There was microscopic involvement of the diaphragm,
omentum, and periaortic nodes, and the cancer was classiﬁed as
International Federation of Gynecology and Obstetrics stage IIIC.
Angiolymphatic invasion was present.
The patient had an uneventful postoperative course and received
six cycles of adjuvant chemotherapy with carboplatin and etoposide.
She did not suffer any signiﬁcant toxicity from the chemotherapy,
with the exception of grade 1 myelosuppression and neuropathy.
The patient never exhibited any laboratory or clinical sign of
hypercalcemia throughout her presentation. She currently exhibits
no evidence of recurrence at 33 months since her surgery.
Pathologic Description
Gross Features
The right ovary and fallopian tube weighed 278 g and included
an intact right ovary measuring 18.0  13.5  11 cm with a
mottled pink-purple surface. Serial sections of the ovarian mass
revealed a multiloculated and ﬂeshy cut surface, with the cysts
containing thin, clear ﬂuid, yellow gelatinous material, and gray-
white grumous material with associated strands of hair. Areas of
softening consistent with necrosis were identiﬁed (Fig. 1).
Microscopic Description
The malignant neuroendocrine population comprised approxi-
mately 90% of the ovarian tumor mass. The residual teratomatous
component consisted of ectodermally derived epithelium, skin
adnexal structures, and intestinal epithelium. Deﬁnite bronchial
epithelium was not identiﬁed. Immature teratomatous elements
such as embryonic tissues or primitive neural tissue were not seen,
nor were malignantly transformed mature elements other than those
described in Figure 2.Figure 1 Intraoperative Photograph of the Sectioned 18-cm
Right Ovarian Mass. The Image Shows the Mass With
Solid Firm Fleshy tan Areas, Cystic Cavities Filled
With Clear Greenish-brown Fluid, and Grumous
Material With Strands of Hair
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were identiﬁed, and sheets of undifferentiated malignant cells with
a high nuclear-cytoplasmic ratio, nuclear molding, and some larger
cells with small nucleoli, in sheets, trabeculae, and islands, in a
background of teratomatous elements were observed. Mitotic ﬁg-
ures were abundant. Follicle-like structures were not seen. Within
the fallopian tubal lumen, malignant neuroendocrine tissue frag-
ments were identiﬁed. Small-cell carcinoma was also identiﬁed in
the alcohol-ﬁxed Papanicolaou-stained cytologic preparation from
the diaphragmatic smear, the omentum, para-aortic lymph nodes,
and the nodule on the right infundibular pelvic ligament. Of 3 para-
aortic lymph nodes, 2 had metastatic deposits, the largest measuring
2.5 cm with extranodal tumor extension into soft tissue identiﬁed.
Immunohistochemical Features
The malignant cell population was labeled with CD56 (neural
cell adhesion molecule [NCAM], the prototypic natural killer cell
marker; most neuroendocrine cells and tumors with neurosecretory
granules express NCAM protein) (Fig. 3), chromogranin, and
synaptophysin (the latter with weak granular cytoplasmic staining)
(Fig. 4A and 4B). Chromogranin A remains the single most speciﬁc
marker of neuroendocrine differentiation, labeling the cytoplasmic
chromogranin protein stored in secretory granules. Synaptophysin,
a calcium-binding glycoprotein, is the most abundant membrane
protein in synaptic vesicles of neurons, and is present in neuroen-
docrine neoplasms. The Ki-67 (mindbomb E3 ubiquitin protein
ligase 1 [MIB-1]) index was high (> 90%), which is generally
associated with aggressive clinical behavior (Fig. 5). Immunostain
results were negative for intermediate ﬁlaments of cytokeratins
7 and 20 and thyroid transcription factor 1 (TTF-1).
Discussion
MCTs are a common neoplasm of the ovary accounting for 10%
to 20% of all ovarian tumors2,15 and occur most commonly in
the ﬁfth to sixth decade of a patient’s life.4,13,14 However, only 1%
to 2% of MCTs undergo malignant transformation,2,3,16 and theFigure 2 Small-Cell Carcinoma With High Nuclear-Cytoplasmic
Ratio, Nuclear Molding, Karyorrhexis, and Population
of Larger Cells With Nucleoli
Figure 3 CD56 Crisp Membranous Labeling With Neural Cell
Adhesions Molecules
Figure 5 Brisk Ki-67 (MIB0-1 Immunostain) Proliferation
Index
Karina E. Hew et almajority of these are squamous cell carcinomas.4,5 However, there
have been only 3 case reports in the English literature of small-cell
carcinoma of the ovary arising from a MCT.6-8 In contrast, primary
small-cell carcinomas of the ovaries are described more frequently
in the literature and have been subclassiﬁed into pulmonary and hy-
percalcemic subtypes.9 These 2 subtypes have characteristic pathologic,
ultrastructural, ﬂow cytometric, and immunohistochemical features.
Attempts at distinguishing between ovarian small-cell carcinoma
of the hypercalcemic type and pulmonary type utilizes clinical in-
formation including patient age, serum calcium levels, and whether
tumor is unilateral or bilateral.9 Histologic features including
the presence of follicular spaces; the presence of a large-cell com-
ponent; and the presence of an associated endometrioid, mucinous,
or Brenner tumor are utilized to help classify the 2 entities.9,10
Additionally, vimentin expression and DNA content are examined
by ﬂow cytometry.9
This patient exhibited mixed features of both the pulmonary
and hypercalcemic subtype. Her age, the absence of postopera-
tive elevated serum calcium levels, and the lack of follicle-like
spaces favored a pulmonary subtype. However, the presence of a
population of large cells with prominent nucleoli and no associatedFigure 4 Cytoplasmic Secretory Granules Show Positive ImmunohistoBrenner or endometrioid component were more indicative of the
hypercalcemic type. Although no bronchial epithelium was identi-
ﬁed, it is postulated that small-cell carcinoma arose from a malig-
nant transformation of a mature element within the teratoma. This
was similar to the ﬁndings noted by Chang et al, where bronchial
epithelium was also not identiﬁed among the mature teratomatous
elements.8 In the case report by Ikota et al, it was postulated that
the adenocarcinoma arose from an intestinal epithelium in the
teratoma, which then differentiated into pulmonary type small-cell
carcinoma among other types of carcinomas.6
Primary small-cell carcinomas of the ovary have been well
described in the literature and arise in the background of epi-
thelialestromal tumors.9 These tumors exhibit aggressive biological
behavior with frequent relapses; they are usually treated with a
multidisciplinary approach using combined surgery, chemotherapy,
and occasionally radiation. There is no randomized study of these
tumors, and the majority of data originate from institutional
experience and case series.11,17,18 The actual optimal sequence of
various treatment modalities such as adjuvant versus neoadjuvant
systemic chemotherapy has not been determined. In most cases,
patients have received multiple cycles of platinum-basedchemistry Staining for (A) Synaptophysin and (B) Chromogranin A
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Table 1 Small-Cell Carcinomas Arising in Association With a Mature Cystic Teratoma
Authors Stage (FIGO) Ovary Site Size, cm Histologic Subtype Treatment Survival, months Prognosis
Hew et ala IIIC Right 18 Mixed Surgery þ etoposide/
carboplatin  6 cycles
33 NED
Ikota et al6 IA Left 12 Pulmonary Surgery 10 NED
Lim et al7 IV Left 28 Pulmonary Surgery þ etoposide/
bleomycin/cisplatin  6 cycles
34 NED
Chang e al8 IA Left 20 Pulmonary Surgery þ cisplatin/
doxorubicin (Adriamycin)/
cyclophosphamide  8 cycles
84 NED
Abbreviations: FIGO ¼ International Federation of Gynecology and Obstetrics; NED ¼ no evidence of disease.
aIndex case.
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56 -chemotherapy in the adjuvant setting, with or without concomitant
radiation therapy.11,14,17,18 One study looked at a fertility-sparing
approach to treating advanced-stage, primary, small-cell ovarian
cancer with a disease-free survival of  60 months.19 Whereas most
patients appear to have tolerated multiagent chemotherapy well,
the risk of long-term toxicity, such as the incidence of myelodys-
plastic syndromes and secondary bone marrow neoplasias, is recog-
nized in small-cell lung cancer and has not been studied in women
with primary small-cell ovarian cancer.20
Because of the rarity of this type of malignant transformation, the
treatment has been similar to that of primary small-cell carcinoma of
the ovary. Clinicopathological characteristics, treatment regimens,
and clinical outcomes of the 4 cases that have been reported are
summarized in Table 1. All 4 patients, including our case, had a
complete response to treatment and showed no evidence of disease
with follow-up periods ranging from 10 to 84 months. Chen et al
found that survival was signiﬁcantly affected by cancer stage and
optimal cytoreduction in patients with malignant transformation
of MCT.13 However, there was no patient with small-cell carcinoma
in their study population. More recent data from Sakuma et al, who
studied 20 cases of transformed malignancies of the ovary retro-
spectively, suggested that postoperative chemotherapy with plat-
inum and taxane combination could improve clinical outcomes.14
However, the majority of their patients had undergone trans-
formation to a squamous cell carcinoma.
To our knowledge, our case of an exceedingly rare small-cell
carcinoma transformed from MCT of the ovary demonstrates one
of the longest reported remissions after cytoreduction and systemic
chemotherapy with a platinum-based regimen. The combination of
etoposide and carboplatin that was used, is the standard treatment
for small-cell lung cancer. Though, in fact our patient did not have
all the features of the pulmonary subtype.
The prognostic signiﬁcance of this uncommon subtype of ovarian
cancer is difﬁcult to discern, as there are only 4 reported cases,
including the case reported in this article. Therefore, large population-
adjusted epidemiologic studies should be implemented to further
evaluate the clinical impact of this rare entity.18,21
Conclusion
Small-cell carcinomas of ovary arising from a malignant trans-
formation of an MCT are very rare entities, with only a few cases
reported. Whether there are any differences in clinical outcomesClinical Ovarian and Other Gynecologic Cancer December 2013between primary and transformed small-cell carcinoma of the ovary
remains uncertain. The optimal management of these tumors is
not well deﬁned, although in most centers they are treated with a
multidisciplinary approach that includes multiagent platinum-
based chemotherapy. Although optimal cytoreduction remains
the main treatment modality, we report a long-term follow-up of
a patient remaining in prolonged remission after postoperative
chemotherapy with a small-cell lung cancerelike regimen. In the
future, molecular characterization of these tumors may aid in
the design and implementation of more effective therapies for this
type of cancer.Acknowledgments
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